- Home
- UFCS vs KURA Comparison
UFCS vs KURA Comparison
Compare UFCS & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UFCS
- KURA
- Stock Information
- Founded
- UFCS 1946
- KURA 2014
- Country
- UFCS United States
- KURA United States
- Employees
- UFCS N/A
- KURA N/A
- Industry
- UFCS Property-Casualty Insurers
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UFCS Finance
- KURA Health Care
- Exchange
- UFCS Nasdaq
- KURA Nasdaq
- Market Cap
- UFCS 679.4M
- KURA 611.7M
- IPO Year
- UFCS N/A
- KURA N/A
- Fundamental
- Price
- UFCS $25.47
- KURA $8.25
- Analyst Decision
- UFCS Hold
- KURA Strong Buy
- Analyst Count
- UFCS 1
- KURA 10
- Target Price
- UFCS $28.00
- KURA $27.13
- AVG Volume (30 Days)
- UFCS 149.2K
- KURA 1.7M
- Earning Date
- UFCS 02-11-2025
- KURA 02-26-2025
- Dividend Yield
- UFCS 2.44%
- KURA N/A
- EPS Growth
- UFCS N/A
- KURA N/A
- EPS
- UFCS 2.39
- KURA N/A
- Revenue
- UFCS $1,253,307,000.00
- KURA N/A
- Revenue This Year
- UFCS N/A
- KURA N/A
- Revenue Next Year
- UFCS $9.59
- KURA $280.91
- P/E Ratio
- UFCS $10.96
- KURA N/A
- Revenue Growth
- UFCS 14.41
- KURA N/A
- 52 Week Low
- UFCS $18.04
- KURA $6.98
- 52 Week High
- UFCS $31.70
- KURA $24.17
- Technical
- Relative Strength Index (RSI)
- UFCS 44.80
- KURA 47.12
- Support Level
- UFCS $24.57
- KURA $7.87
- Resistance Level
- UFCS $27.54
- KURA $8.55
- Average True Range (ATR)
- UFCS 0.96
- KURA 0.55
- MACD
- UFCS 0.17
- KURA 0.03
- Stochastic Oscillator
- UFCS 32.23
- KURA 43.48
About UFCS United Fire Group Inc.
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.